Advent Venture Raises $120 Million for First Life Sciences Fund

Advent Venture Partners LLP, a London-based investment firm, has raised $120 million for its first life science fund.

The fund will invest in early- to mid-stage life science companies in the U.K., Europe and U.S. and will be managed by partners Shahzad Malik and Raj Parekh, Advent said in an e- mailed statement today.

Advent has invested in PowderMed, which was bought by Pfizer Inc.; Thiakis, which was purchased by Wyeth, and Respivert, which was bought by Johnson & Johnson.

To contact the reporter on this story: Chris Kay in London at ckay5@bloomberg.net

To contact the editors responsible for this story: Phil Serafino at pserafino@bloomberg.net

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.